drugset
drugset / Trial / NCT04660305

AT278 and NovoRapid® in Glucose Clamp Study

NCT04660305 ↗

Phase 1 Completed 38 enrolled Arecor Limited
RandomizedCrossoverQuadruple-blindTreatment

Summary

A phase 1, randomised, single-centre, double-blind, single-dose, two period balanced cross over study in a glucose clamp setting. The study compares the pharmacodynamic, pharmacokinetic and safety characteristics of AT278 and NovoRapid® in male participants with type 1 diabetes.

Timeline

Start
2020-12-02
Primary completion
2021-06-03
Completion
2021-06-11

Drugs

EvaluationDrugModalityDoseRoute
Subject insulin aspart Protein / enzyme biologic 0.3 iu/kg Subcutaneous

Indications

type 1 diabetes mellitus